The present disclosure is directed to the identification and use of lipids involved in auto-immune reactions and foreign body responses. A. set of phospholipids was observed to preferentially deposit on immune-evasive implants, and these phospholipids upregulated RNA transcripts of anti-inflammatory proteins in murine macrophages. Additionally, a set of fatty acid lipids was observed to preferentially deposit on immunogenic implants, and these fatty acid lipids upregulated RNA transcripts of inflammatory proteins in murine macrophages. Using selected lipids, implantable devices can be engineered to avoid or to attract host immune responses, thereby regulating the length of time the devices are maintained in vivo.

According to various embodiments, a glove is provided with improved hydration characteristics and low dermatitis potential. The glove comprises a substrate and a polymer system that coats a surface of the substrate. The polymer system comprises: a polyol, a botanical extract, an emollient agent, a silicone copolymer dispersion, a lubricant, and a surfactant. The substrate may be free of sulphur and accelerators. An example formulation of the polymer system may comprise glycerol, Aloe vera, a carnauba wax dispersion, dimethicone, a polyalkylene glycol (PAG), and polyoxyethylene (20) sorbitan monooleate. The polymer system may be applied to the\surface of the substrate by dipping the surface into a water-based dispersion of the polymer system, or spraying the water-based dispersion onto the interior surface. The polymer system may be blended into water at a total solids content of 0.8% to 1.2% w/w to form the water-based dispersion.

Compositions of fatty acids (e.g., including one or more C4 to C40 fatty acids, such as a C4 to C20 fatty acid) and one or more amino acids (and particularly one or more amino acids having electrically charged basic side chains, e.g., Arginine, Lysine, etc.) for use as an anti-pathogenic composition. These compositions may find particular use as anti-bacterial and in some variations anti-viral, anti-fungal and anti-cancer compositions.

An apoptosis-mimicking structure includes a polymeric core. The polymeric core includes a polymer backbone. The polymer backbone includes or is modified with a functional group to directly or indirectly bond to an eat me signaling molecule. An eat me signaling molecule is bonded directly or indirectly to the functional group. Other structures include a scaffold and the apoptosis-mimicking structure immobilized on or incorporated into the scaffold.

An ostomy skin barrier composition includes a water-insoluble pressure-sensitive adhesive component, a hydrophilic component, and at least three different types of lipids including ceramide, cholesterol, and fatty acids. The skin barrier composition is configured to provide skin barriers having adhesive characteristics suitable for ostomy applications to securely attach an ostomy pouch to user's peristomal skin, while minimizing peristomal skin irritation and injuries.

A prosthesis including a UHMWPE core and a coating, wherein the core is a cup-shaped core having a concave first side and a convex second side, wherein the UHMWPE has a weight average molecular weight that is from 210.sup.6 to 310.sup.6 grams per mole. The core has a tensile strength that is from 35 to 50 MPa. The coating layer coats the second side of the core. The coating includes titanium powder having a D50 particle size of from 200 to 250 microns. The coating has a mean thickness that is from 200 to 500 microns. The prosthesis is an acetabular cup prosthesis. When tested for abrasion resistance, the coating loses less than 65 milligrams when abraded for 100 cycles. The coating has a static shear bond strength that is from 15 to 25 MPa and a static tensile bond strength that is from 14 to 25 MPa.

Newly designed polymeric compounds (lipid-polymer conjugates), which are usable for forming lipid bilayers and liposomes comprising same, lipid bilayers and liposomes formed thereby and uses thereof are disclosed. Newly designed processes of preparing polymeric compounds (lipid-polymer conjugates) are also disclosed.